Latest Breaking News On - Chief development adviser - Page 1 : comparemela.com

/PRNewswire/ CellCentric, a clinical stage, private biotechnology company pioneering small molecule inhibition of p300/CBP to treat cancer, today announces.

United kingdomAndrew hughesPrnewswire cellcentricKris freseDevelopment adviserAstrazeneca pharmaceuticalsScientist at cancer research united kingdomCancer biomarker centre preclinical pharmacology teamUniversity of manchesterCancer research united kingdomChief development adviserCancer biologyAssociate scientistCancer biomarker centre preclinical pharmacologyHonorary professorExperimental cancer medicine